DKCM
BIIB icon

Davidson Kempner Capital Management’s Biogen BIIB Stock Holding History

Davidson Kempner Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50,000
Closed -$13.7M – 170
2017
Q1 		$13.7M Sell
50,000
-62,751
-56% -$17.7M 0.16% 92
2016
Q4 		$32M Buy
112,751
+42,751
+61% +$12.7M 0.65% 34
2016
Q3 		$21.9M Buy
+70,000
New +$20.7M 0.54% 47

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Davidson Kempner Capital Management's BIIB Position: Q2 2017 in Review

Davidson Kempner Capital Management sold out of Biogen (BIIB) in Q2 2017, closing a stake of 50,000 shares — an estimated $13.7M sold.

Davidson Kempner Capital Management first reported a position in BIIB in Q3 2016 and held it in 3 quarters. The position peaked at $32M in Q4 2016. 993 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Davidson Kempner Capital Management reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 50,000 Biogen shares in Q2 2017, an estimated $13.7M.
  • Davidson Kempner Capital Management first reported a position in Biogen in Q3 2016 and held it in 3 quarters.
  • Davidson Kempner Capital Management's Biogen position peaked at $32M in Q4 2016.
  • 993 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.